Re: James J. Hsieh, David Chen, Patricia I. Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405-14

Lei Ye; Yildiz Serdar; Chen Minfeng

首页> 外文期刊>European urology >Re: James J. Hsieh, David Chen, Patricia I. Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405-14

【24h】

Re: James J. Hsieh, David Chen, Patricia I. Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405-14

机译：Re：James J. Hsieh，David Chen，Patricia I. Wang，等。随机试验的基因组生物标志物比较第一线Everolimus和Sunitinib在转移性肾细胞癌患者中的基因组生物标志物。 EUR UROL 2017; 71：405-14

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European urology》 |2017年第3期|共2页
作者
Lei Ye; Yildiz Serdar; Chen Minfeng;
展开▼
作者单位

Cent S Univ Xiangya Hosp Dept Urol Changsha 410008 Hunan Peoples R China;

Diakonie Klinikum Stuttgart Dept Urol Stuttgart Germany;

Cent S Univ Xiangya Hosp Dept Urol Changsha 410008 Hunan Peoples R China;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词

相似文献

外文文献

1. Re: James J. Hsieh, David Chen, Patricia I. Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405-14 [J] . Lei Ye, Yildiz Serdar, Chen Minfeng European urology . 2017,第3期

机译：Re：James J. Hsieh，David Chen，Patricia I. Wang，等。随机试验的基因组生物标志物比较第一线Everolimus和Sunitinib在转移性肾细胞癌患者中的基因组生物标志物。 EUR UROL 2017; 71：405-14
2. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma [J] . Hsieh James J., Chen David, Wang Patricia I., European urology . 2017,第3期

机译：随机试验的基因组生物标志物比较第一线艾莫姆斯和孙氨虫患者转移性肾细胞癌
3. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma [J] . MotzerR.J., BarriosC.H., KimT.M., Journal of Clinical Oncology . 2014,第25期

机译：II期随机试验比较了转移性肾细胞癌患者一线依维莫司和二线舒尼替尼与一线舒尼替尼和二线依维莫司的比较
4. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma [O] . James J. Hsieh, David Chen, Patricia I. Wang, -1

机译：一线依维莫司和舒尼替尼治疗转移性肾细胞癌患者的随机试验的基因组生物标志物
5. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma [O] . James J. Hsieh, David Chen, Patricia I. Wang, 2017

机译：随机试验的基因组生物标志物比较第一线艾莫姆斯和孙尼替尼在转移性肾细胞癌患者中的肝癌

Re: James J. Hsieh, David Chen, Patricia I. Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405-14

著录项

相似文献

相关主题

期刊订阅